Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Leukemia

  Free Subscription


11.03.2019

2 Am J Hematol
2 Ann Hematol
1 BMC Cancer
4 Bone Marrow Transplant
1 Eur J Immunol
1 Genomics
4 Int J Hematol
1 J Biol Chem
1 Leuk Lymphoma
2 Leuk Res
4 Leukemia
1 N Engl J Med
1 Oncogene
2 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Hematol

  1. ABBAS HA, Ravandi F, Loghavi S, Patel KP, et al
    NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated AML.
    Am J Hematol. 2019 Mar 5. doi: 10.1002/ajh.25454.
    PubMed     Text format    

  2. CALDWELL I, Ruskova A, Royle G, Liang J, et al
    Pure erythroid leukemia: The value of E-cadherin in making the diagnosis.
    Am J Hematol. 2019 Feb 17. doi: 10.1002/ajh.25437.
    PubMed     Text format    


    Ann Hematol

  3. KARAI B, Habok M, Remenyi G, Rejto L, et al
    A novel flow cytometric method for enhancing acute promyelocytic leukemia screening by multidimensional dot-plots.
    Ann Hematol. 2019 Mar 4. pii: 10.1007/s00277-019-03642.
    PubMed     Text format     Abstract available

  4. OYAKE T, Takemasa-Fujisawa Y, Sugawara N, Mine T, et al
    Doripenem versus meropenem as first-line empiric therapy of febrile neutropenia in patients with acute leukemia: a prospective, randomized study.
    Ann Hematol. 2019 Mar 1. pii: 10.1007/s00277-019-03634.
    PubMed     Text format     Abstract available


    BMC Cancer

  5. RICHTER A, Roolf C, Hamed M, Gladbach YS, et al
    Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
    BMC Cancer. 2019;19:202.
    PubMed     Text format     Abstract available


    Bone Marrow Transplant

  6. HEMMATI PG, Pfeifer K, Vuong LG, Jehn CF, et al
    Allogeneic stem cell transplantation for non-de novo AML or advanced myelodysplastic syndromes: influence of GvHD and donor lymphocyte infusions on long-term outcome.
    Bone Marrow Transplant. 2017 Oct 9. doi: 10.1038/bmt.2017.
    PubMed     Text format    

  7. RASHIDI A, Linden MA, Percival ME, Sandmaier BM, et al
    Recommendations for reporting post-transplant relapse in AML.
    Bone Marrow Transplant. 2018;53:111-113.
    PubMed     Text format    

  8. WAIS V, Kundgen L, Bohl SR, von Harsdorf S, et al
    Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.
    Bone Marrow Transplant. 2018;53:94-96.
    PubMed     Text format    

  9. ZHANG Q, Zhou Y, Majaw JK, Xu J, et al
    Acute appendicitis in leukaemia patients undergoing haematopoietic stem cell transplantation during the neutropaenic phase: a case series from a single BMT centre in China.
    Bone Marrow Transplant. 2018;53:219-222.
    PubMed     Text format    


    Eur J Immunol

  10. GRUNBERG M, Quandt D, Cynis H, Demuth HU, et al
    Kallikrein-related peptidases are activators of the CC chemokine CCL14.
    Eur J Immunol. 2018;48:1592-1594.
    PubMed     Text format     Abstract available


    Genomics

  11. YASSI M, Shams Davodly E, Mojtabanezhad Shariatpanahi A, Heidari M, et al
    DMRFusion: A differentially methylated region detection tool based on the ranked fusion method.
    Genomics. 2018;110:366-374.
    PubMed     Text format     Abstract available


    Int J Hematol

  12. UEDA T, Maeda T, Kusakabe S, Fujita J, et al
    Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation.
    Int J Hematol. 2018 Nov 17. pii: 10.1007/s12185-018-2562.
    PubMed     Text format     Abstract available

  13. TOBINAI K, Uchida T, Fukuhara N, Nishikawa T, et al
    Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.
    Int J Hematol. 2019;109:366-368.
    PubMed     Text format    

  14. SASAKI K, Kantarjian HM, O'Brien S, Ravandi F, et al
    Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Int J Hematol. 2019 Mar 4. pii: 10.1007/s12185-019-02620.
    PubMed     Text format     Abstract available

  15. ARAI N, Homma M, Abe M, Baba Y, et al
    Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia.
    Int J Hematol. 2019 Mar 7. pii: 10.1007/s12185-019-02616.
    PubMed     Text format     Abstract available


    J Biol Chem

  16. DUGGIMPUDI S, Kloetgen A, Maney SK, Munch PC, et al
    Transcriptome-wide analysis uncovers the targets of the RNA-binding protein MSI2 and effects of MSI2's RNA-binding activity on IL-6 signaling.
    J Biol Chem. 2018;293:15359-15369.
    PubMed     Text format     Abstract available


    Leuk Lymphoma

  17. NAYMAGON L, Moshier E, Tremblay D, Mascarenhas J, et al
    Predictors of early hemorrhage in acute promyelocytic leukemia.
    Leuk Lymphoma. 2019 Mar 8:1-10. doi: 10.1080/10428194.2019.1581187.
    PubMed     Text format     Abstract available


    Leuk Res

  18. KING AC, Pappacena JJ, Tallman MS, Park JH, et al
    Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
    Leuk Res. 2019;79:27-33.
    PubMed     Text format     Abstract available

  19. JARAMILLO AC, Cloos J, Lemos C, Stam RW, et al
    Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.
    Leuk Res. 2019;79:45-51.
    PubMed     Text format     Abstract available


    Leukemia

  20. BHOJWANI D, Sposto R, Shah NN, Rodriguez V, et al
    Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
    Leukemia. 2019 Mar 7. pii: 10.1038/s41375-019-0426.
    PubMed     Text format     Abstract available

  21. BASTIAN L, Schroeder MP, Eckert C, Schlee C, et al
    PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2019 Mar 6. pii: 10.1038/s41375-019-0430.
    PubMed     Text format     Abstract available

  22. CANAANI J, Labopin M, Itala-Remes M, Blaise D, et al
    Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia.
    Leukemia. 2019 Mar 7. pii: 10.1038/s41375-019-0439.
    PubMed     Text format     Abstract available

  23. HE X, Xiao X, Li Q, Jiang Y, et al
    Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL.
    Leukemia. 2019 Mar 7. pii: 10.1038/s41375-019-0437.
    PubMed     Text format    


    N Engl J Med

  24. SOUMERAI JD, Tajmir SH, Hirsch MS, Massoth LR, et al
    Case 7-2019: A 73-Year-Old Woman with Swelling of the Right Groin and Fever.
    N Engl J Med. 2019;380:859-868.
    PubMed     Text format    


    Oncogene

  25. NICOLAE CM, O'Connor MJ, Constantin D, Moldovan GL, et al
    NFkappaB regulates p21 expression and controls DNA damage-induced leukemic differentiation.
    Oncogene. 2018;37:3647-3656.
    PubMed     Text format     Abstract available


    PLoS One

  26. MULU FENTIE A, Tadesse F, Engidawork E, Gebremedhin A, et al
    Prevalence and determinants of non-adherence to Imatinib in the first 3-months treatment among newly diagnosed Ethiopian's with chronic myeloid leukemia.
    PLoS One. 2019;14:e0213557.
    PubMed     Text format     Abstract available

  27. KITAMURA H, Tabe Y, Ai T, Tsuchiya K, et al
    A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
    PLoS One. 2019;14:e0207170.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: